<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02285998</url>
  </required_header>
  <id_info>
    <org_study_id>PSC12</org_study_id>
    <nct_id>NCT02285998</nct_id>
  </id_info>
  <brief_title>Protective Efficacy of Flublok® Quadrivalent Versus Licensed Inactivated Influenza Vaccine in Adults ≥50 Years of Age</brief_title>
  <official_title>Comparison of the Protective Efficacy of Flublok® Quadrivalent Versus Licensed Inactivated Influenza Vaccine (IIV4) in Healthy, Medically Stable Adults ≥50 Years of Age</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Protein Sciences Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Protein Sciences Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this study is to establish that Flublok Quadrivalent is non-inferior to fully
      licensed (traditional approval status) quadrivalent inactivated influenza vaccine (IIV4) in
      protecting against laboratory-confirmed clinical influenza disease in the ≥50 year age
      population.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The goal of this study is to establish that Flublok Quadrivalent is non-inferior to fully
      licensed (traditional approval status) quadrivalent inactivated influenza vaccine (IIV4) in
      protecting against laboratory-confirmed clinical influenza disease in the ≥50 year age
      population. Real-time Polymerase Chain Reaction (rtPCR) will be used to confirm influenza
      infection and to type the strains involved, as molecular methodologies have been demonstrated
      to be more sensitive than other more traditional methodologies, e.g. culture. For
      rtPCR-positive clinical samples, reserved aliquots will be processed for culture, so that
      antigenic similarity to the HA present in study vaccines can be tested.

      In various clinical studies the investigators demonstrated that the immune response against
      the influenza A viruses is improved as a result of the higher hemagglutinin content.
      Furthermore, influenza virus disease and hospitalization associated with influenza-related
      illness in older adults (&gt; 50 years) was considerably reduced (90%) following vaccination
      with TIV, even though the circulating influenza A strain was antigenically dissimilar to that
      in the vaccine. However, more recently Skowronski et al. reported that the low influenza
      vaccine effectiveness in 2012-2013 was not associated with antigenic drift but was instead
      related to mutations in the egg-adapted H3N2 vaccine strain. Flublok manufactured using
      recombinant technology does not contain the mutations responsible for the reported lower
      effectiveness and may thus offer improved protection when mutations such as those described
      are induced in the process of adapting the influenza virus to growth in eggs.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Actual">May 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With rtPCR-confirmed Influenza-Like Illness</measure>
    <time_frame>14 days post vaccination through and up to 32 weeks post vaccination</time_frame>
    <description>rtPCR-confirmed, protocol-defined Influenza-Like Illness (ILI) caused by any influenza strain that begins at least 14 days post-vaccination</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Culture-confirmed Influenza-Like Illness</measure>
    <time_frame>14 days post vaccination through and up to 32 weeks post vaccination</time_frame>
    <description>Culture-confirmed protocol-defined Influenza-Like Illness (ILI) that begins at least 14 days post-vaccination caused by an influenza strain (identified from the same clinical sample) antigenically matched to those strains represented in the study vaccines.
Protocol-defined ILI is defined as at least one of the following respiratory symptoms accompanied by at least one of the following systemic symptoms:
Respiratory symptoms: sore throat, cough, sputm production, wheezing, difficulty breathing Systemic symptoms: fever, chills (shivering), tiredness (fatigue), headache, myalgia (muscle ache)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Culture-confirmed CDC-defined Influenza-Like Illness</measure>
    <time_frame>14 days post vaccination through and up to 32 weeks post vaccination</time_frame>
    <description>Culture-confirmed CDC-defined Influenza-Like Illness (ILI) that begins at least 14 days post-vaccination caused by an influenza strain (identified from the same clinical sample) antigenically matched to those in the study vaccines.
CDC-defined ILI is defined as body temperature ≥100°F accompanied by cough and/or sore throat.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With rtPCR-confirmed CDC-defined Influenza-Like Illness</measure>
    <time_frame>14 days post vaccination through and up to 32 weeks post vaccination</time_frame>
    <description>rtPCR-confirmed CDC-defined ILI that begins at least 14 days post-vaccination caused by any influenza strain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Seroconversion</measure>
    <time_frame>Days 0 through 28</time_frame>
    <description>Seroconversion rates (SCR) for all four antigens in a preselected subset of subjects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Local Injection Site Reactogenicity</measure>
    <time_frame>Days 0 through 7</time_frame>
    <description>Solicited events of injection site reactogenicity reported during Day 0-7.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Unsolicited Adverse Events</measure>
    <time_frame>Days 0 through 28</time_frame>
    <description>Unsolicited adverse events reported in the 28 days following vaccine administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Serious Adverse Events (SAEs) and Medically-attended Adverse Events (MAEs)</measure>
    <time_frame>Day 0 through and up to 32 weeks post vaccination</time_frame>
    <description>Serious adverse events (SAEs) and medically-attended adverse events (MAEs) occurring during the period of follow-up through the influenza season (at least 6 months post-vaccination).
A MAE is an event that prompts an unplanned visit to a medical professional for diagnosis and/or treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure of Post-vaccination HAI GMTs</measure>
    <time_frame>Days 0 through 28</time_frame>
    <description>GMT titers for all four antigens in a preselected subset of subjects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Systemic Reactogenicity</measure>
    <time_frame>Days 0 through 7</time_frame>
    <description>Solicited events of systemic reactogenicity reported during Day 0-7.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">9003</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>Flublok Quadrivalent Influenza Vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intramuscular injection of vaccine containing 4 x 45µg (180µg total) of each recombinant hemagglutinin (rHA) derived from influenza A/H1N1 and A/H3N2 and two lineages of influenza B viruses identified for the season in which the trial is conducted in a total volume of 0.5 mL</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Inactivated Influenza Vaccine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intramuscular injection of vaccine contains 4 x 15µg (60µg total) of HA derived from the same influenza A/H1N1 and A/H3N2 and influenza B strains in a total volume of 0.5mL.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Flublok Quadrivalent Influenza Vaccine</intervention_name>
    <description>Intramuscular injection of vaccine</description>
    <arm_group_label>Flublok Quadrivalent Influenza Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Inactivated Influenza Vaccine</intervention_name>
    <description>Intramuscular injection of vaccine</description>
    <arm_group_label>Inactivated Influenza Vaccine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Ambulatory adults aged 50 and older.

          2. Medically stable, as determined by medical history and targeted physical examination.
             &quot;Medically stable&quot; is defined as no change in diagnoses or chronic medications (dose
             or class) for medical reasons in the 3 months prior to study.

          3. Absence of underlying conditions that make participation in the study contrary to the
             subject's best interest.

          4. Able to understand and comply with planned study procedures.

          5. Provides written informed consent prior to initiation of any study procedure.

        Exclusion Criteria:

          1. Known contraindication to either study vaccine (see product package inserts)

          2. Receipt of any other influenza vaccine within 180 days prior to enrollment in this
             study.

          3. Underlying disease or ongoing therapy that might cause immunocompromise, e.g.
             cytotoxic agents or supraphysiologic doses of corticosteroids, such that response to
             vaccination might be sub-optimal.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Coastal Clinical Research</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Consortium Arizona</name>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <zip>85283</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baptist Health Center for Clinical Research</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northern California Clinical Research Center</name>
      <address>
        <city>Redding</city>
        <state>California</state>
        <zip>96001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Benchmark Research - Sacramento</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95816</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Benchmark Research - San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lynn Institute of the Rockies</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80907</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Consulting</name>
      <address>
        <city>Milford</city>
        <state>Connecticut</state>
        <zip>06460</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research of South Florida</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Avail Clinical Research</name>
      <address>
        <city>DeLand</city>
        <state>Florida</state>
        <zip>32720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Westside Center for Clinical Research</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jacksonville Center for Clinical Research</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Progressive Medical Research</name>
      <address>
        <city>Port Orange</city>
        <state>Florida</state>
        <zip>32127</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meridian Research</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <zip>31406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ACR - Boise</name>
      <address>
        <city>Meridian</city>
        <state>Idaho</state>
        <zip>83642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heartland Research Associates, LLC</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Kentucky Research Associates</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40509</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Benchmarch Research - New Orleans</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ActivMed Practices &amp; Research</name>
      <address>
        <city>Methuen</city>
        <state>Massachusetts</state>
        <zip>01844</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Pharmaceutical Research</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meridian Research</name>
      <address>
        <city>Bellevue</city>
        <state>Nebraska</state>
        <zip>68005</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meridian Research</name>
      <address>
        <city>Norfolk</city>
        <state>Nebraska</state>
        <zip>68701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meridian Clinical Research</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68164</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Consortium-Nevada</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ActivMed Practices &amp; Research</name>
      <address>
        <city>Newington</city>
        <state>New Hampshire</state>
        <zip>03801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Clinical Research, Inc.</name>
      <address>
        <city>Endwell</city>
        <state>New York</state>
        <zip>13760</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rochester Clinical Research</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Research</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rapid Medical Research, Inc.</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lynn Institute of Norman</name>
      <address>
        <city>Norman</city>
        <state>Oklahoma</state>
        <zip>73069</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lynn Health Science Institute</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meridian Research</name>
      <address>
        <city>Dakota Dunes</city>
        <state>South Dakota</state>
        <zip>57049</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Associates</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Benchmark Reseach</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Benchmark Research - Fort Worth</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Benchmark Research - San Angelo</name>
      <address>
        <city>San Angelo</city>
        <state>Texas</state>
        <zip>76904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jean Brown Research</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Associates of Tidewater</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.flublok.com</url>
    <description>Flublok Influenza Vaccine</description>
  </link>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 27, 2014</study_first_submitted>
  <study_first_submitted_qc>November 4, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 7, 2014</study_first_posted>
  <results_first_submitted>August 3, 2016</results_first_submitted>
  <results_first_submitted_qc>August 10, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 4, 2016</results_first_posted>
  <last_update_submitted>September 26, 2017</last_update_submitted>
  <last_update_submitted_qc>September 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Influenza</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Excludes 40 subjects who received randomization numbers, but who either withdrew prior to vaccination (n=15) or for whom the vaccine received could not be verified (n=25; 12 assigned to Flublok quadrivalent and 13 assigned to IIV4).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Flublok Quadrivalent Influenza Vaccine</title>
          <description>Intramuscular injection of vaccine containing 4 x 45µg (180µg total) of each recombinant hemagglutinin (rHA) derived from influenza A/H1N1 and A/H3N2 and two lineages of influenza B viruses identified for the season in which the trial is conducted in a total volume of 0.5 mL
Flublok Quadrivalent Influenza Vaccine: Intramuscular injection of vaccine</description>
        </group>
        <group group_id="P2">
          <title>Inactivated Influenza Vaccine</title>
          <description>Intramuscular injection of vaccine contains 4 x 15µg (60µg total) of HA derived from the same influenza A/H1N1 and A/H3N2 and influenza B strains in a total volume of 0.5mL.
Inactivated Influenza Vaccine: Intramuscular injection of vaccine</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4474"/>
                <participants group_id="P2" count="4489"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4228"/>
                <participants group_id="P2" count="4236"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="246"/>
                <participants group_id="P2" count="253"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="176"/>
                <participants group_id="P2" count="172"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="53"/>
                <participants group_id="P2" count="61"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other Reasons</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The safety population included all randomized subjects who received known study vaccine and for whom some safety data were available after administration of vaccine.</population>
      <group_list>
        <group group_id="B1">
          <title>Flublok Quadrivalent Influenza Vaccine</title>
          <description>Intramuscular injection of vaccine containing 4 x 45µg (180µg total) of each recombinant hemagglutinin (rHA) derived from influenza A/H1N1 and A/H3N2 and two lineages of influenza B viruses identified for the season in which the trial is conducted in a total volume of 0.5 mL
Flublok Quadrivalent Influenza Vaccine: Intramuscular injection of vaccine</description>
        </group>
        <group group_id="B2">
          <title>Inactivated Influenza Vaccine</title>
          <description>Intramuscular injection of vaccine contains 4 x 15µg (60µg total) of HA derived from the same influenza A/H1N1 and A/H3N2 and influenza B strains in a total volume of 0.5mL.
Inactivated Influenza Vaccine: Intramuscular injection of vaccine</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4328"/>
            <count group_id="B2" value="4344"/>
            <count group_id="B3" value="8672"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>50-64 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2569"/>
                    <measurement group_id="B2" value="2617"/>
                    <measurement group_id="B3" value="5186"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>65-74 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1234"/>
                    <measurement group_id="B2" value="1254"/>
                    <measurement group_id="B3" value="2488"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>75 years and older</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="525"/>
                    <measurement group_id="B2" value="473"/>
                    <measurement group_id="B3" value="998"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2532"/>
                    <measurement group_id="B2" value="2537"/>
                    <measurement group_id="B3" value="5069"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1796"/>
                    <measurement group_id="B2" value="1807"/>
                    <measurement group_id="B3" value="3603"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With rtPCR-confirmed Influenza-Like Illness</title>
        <description>rtPCR-confirmed, protocol-defined Influenza-Like Illness (ILI) caused by any influenza strain that begins at least 14 days post-vaccination</description>
        <time_frame>14 days post vaccination through and up to 32 weeks post vaccination</time_frame>
        <population>The efficacy population includes all randomized subjects who received study vaccine and provided any follow-up for ILI beginning at least 14 days following vaccine administration.</population>
        <group_list>
          <group group_id="O1">
            <title>Flublok Quadrivalent Influenza Vaccine</title>
            <description>Intramuscular injection of vaccine containing 4 x 45µg (180µg total) of each recombinant hemagglutinin (rHA) derived from influenza A/H1N1 and A/H3N2 and two lineages of influenza B viruses identified for the season in which the trial is conducted in a total volume of 0.5 mL
Flublok Quadrivalent Influenza Vaccine: Intramuscular injection of vaccine</description>
          </group>
          <group group_id="O2">
            <title>Inactivated Influenza Vaccine</title>
            <description>Intramuscular injection of vaccine contains 4 x 15µg (60µg total) of HA derived from the same influenza A/H1N1 and A/H3N2 and influenza B strains in a total volume of 0.5mL.
Inactivated Influenza Vaccine: Intramuscular injection of vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With rtPCR-confirmed Influenza-Like Illness</title>
          <description>rtPCR-confirmed, protocol-defined Influenza-Like Illness (ILI) caused by any influenza strain that begins at least 14 days post-vaccination</description>
          <population>The efficacy population includes all randomized subjects who received study vaccine and provided any follow-up for ILI beginning at least 14 days following vaccine administration.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4303"/>
                <count group_id="O2" value="4301"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96"/>
                    <measurement group_id="O2" value="138"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The primary efficacy analysis was based on the numbers of protocol-defined influenza-like illnesses with rtPCR-positive nasopharyngeal swabs detecting influenza virus of any strain. The Relative Vaccine Efficacy was 30% (10, 47). Non-inferiority would be concluded if the lower bound of the 95% CI for rVE was &gt; -20%. Superiority of RIV4 in a pre-specified exploratory analysis required that the lower bound of the two-sided 95% CI of rVE be &gt; +9%.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The sample size required to achieve 80% power was calculated based on a one-sided alpha level of 0.025 and an attack rate of 2% in the IIV4 and 1.53% for the Flublok groups respectively.</non_inferiority_desc>
            <param_type>Relative Vaccine Efficacy (rVE)</param_type>
            <param_value>30</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>10</ci_lower_limit>
            <ci_upper_limit>47</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Culture-confirmed Influenza-Like Illness</title>
        <description>Culture-confirmed protocol-defined Influenza-Like Illness (ILI) that begins at least 14 days post-vaccination caused by an influenza strain (identified from the same clinical sample) antigenically matched to those strains represented in the study vaccines.
Protocol-defined ILI is defined as at least one of the following respiratory symptoms accompanied by at least one of the following systemic symptoms:
Respiratory symptoms: sore throat, cough, sputm production, wheezing, difficulty breathing Systemic symptoms: fever, chills (shivering), tiredness (fatigue), headache, myalgia (muscle ache)</description>
        <time_frame>14 days post vaccination through and up to 32 weeks post vaccination</time_frame>
        <population>The efficacy population includes all randomized subjects who received study vaccine and provided any follow-up for ILI beginning at least 14 days following vaccine administration.</population>
        <group_list>
          <group group_id="O1">
            <title>Flublok Quadrivalent Influenza Vaccine</title>
            <description>Intramuscular injection of vaccine containing 4 x 45µg (180µg total) of each recombinant hemagglutinin (rHA) derived from influenza A/H1N1 and A/H3N2 and two lineages of influenza B viruses identified for the season in which the trial is conducted in a total volume of 0.5 mL
Flublok Quadrivalent Influenza Vaccine: Intramuscular injection of vaccine</description>
          </group>
          <group group_id="O2">
            <title>Inactivated Influenza Vaccine</title>
            <description>Intramuscular injection of vaccine contains 4 x 15µg (60µg total) of HA derived from the same influenza A/H1N1 and A/H3N2 and influenza B strains in a total volume of 0.5mL.
Inactivated Influenza Vaccine: Intramuscular injection of vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Culture-confirmed Influenza-Like Illness</title>
          <description>Culture-confirmed protocol-defined Influenza-Like Illness (ILI) that begins at least 14 days post-vaccination caused by an influenza strain (identified from the same clinical sample) antigenically matched to those strains represented in the study vaccines.
Protocol-defined ILI is defined as at least one of the following respiratory symptoms accompanied by at least one of the following systemic symptoms:
Respiratory symptoms: sore throat, cough, sputm production, wheezing, difficulty breathing Systemic symptoms: fever, chills (shivering), tiredness (fatigue), headache, myalgia (muscle ache)</description>
          <population>The efficacy population includes all randomized subjects who received study vaccine and provided any follow-up for ILI beginning at least 14 days following vaccine administration.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4303"/>
                <count group_id="O2" value="4301"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                    <measurement group_id="O2" value="101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Culture-confirmed CDC-defined Influenza-Like Illness</title>
        <description>Culture-confirmed CDC-defined Influenza-Like Illness (ILI) that begins at least 14 days post-vaccination caused by an influenza strain (identified from the same clinical sample) antigenically matched to those in the study vaccines.
CDC-defined ILI is defined as body temperature ≥100°F accompanied by cough and/or sore throat.</description>
        <time_frame>14 days post vaccination through and up to 32 weeks post vaccination</time_frame>
        <population>The efficacy population includes all randomized subjects who received study vaccine and provided any follow-up for ILI beginning at least 14 days following vaccine administration.</population>
        <group_list>
          <group group_id="O1">
            <title>Flublok Quadrivalent Influenza Vaccine</title>
            <description>Intramuscular injection of vaccine containing 4 x 45µg (180µg total) of each recombinant hemagglutinin (rHA) derived from influenza A/H1N1 and A/H3N2 and two lineages of influenza B viruses identified for the season in which the trial is conducted in a total volume of 0.5 mL
Flublok Quadrivalent Influenza Vaccine: Intramuscular injection of vaccine</description>
          </group>
          <group group_id="O2">
            <title>Inactivated Influenza Vaccine</title>
            <description>Intramuscular injection of vaccine contains 4 x 15µg (60µg total) of HA derived from the same influenza A/H1N1 and A/H3N2 and influenza B strains in a total volume of 0.5mL.
Inactivated Influenza Vaccine: Intramuscular injection of vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Culture-confirmed CDC-defined Influenza-Like Illness</title>
          <description>Culture-confirmed CDC-defined Influenza-Like Illness (ILI) that begins at least 14 days post-vaccination caused by an influenza strain (identified from the same clinical sample) antigenically matched to those in the study vaccines.
CDC-defined ILI is defined as body temperature ≥100°F accompanied by cough and/or sore throat.</description>
          <population>The efficacy population includes all randomized subjects who received study vaccine and provided any follow-up for ILI beginning at least 14 days following vaccine administration.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4303"/>
                <count group_id="O2" value="4301"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With rtPCR-confirmed CDC-defined Influenza-Like Illness</title>
        <description>rtPCR-confirmed CDC-defined ILI that begins at least 14 days post-vaccination caused by any influenza strain.</description>
        <time_frame>14 days post vaccination through and up to 32 weeks post vaccination</time_frame>
        <population>The efficacy population includes all randomized subjects who received study vaccine and provided any follow-up for ILI beginning at least 14 days following vaccine administration.</population>
        <group_list>
          <group group_id="O1">
            <title>Flublok Quadrivalent Influenza Vaccine</title>
            <description>Intramuscular injection of vaccine containing 4 x 45µg (180µg total) of each recombinant hemagglutinin (rHA) derived from influenza A/H1N1 and A/H3N2 and two lineages of influenza B viruses identified for the season in which the trial is conducted in a total volume of 0.5 mL
Flublok Quadrivalent Influenza Vaccine: Intramuscular injection of vaccine</description>
          </group>
          <group group_id="O2">
            <title>Inactivated Influenza Vaccine</title>
            <description>Intramuscular injection of vaccine contains 4 x 15µg (60µg total) of HA derived from the same influenza A/H1N1 and A/H3N2 and influenza B strains in a total volume of 0.5mL.
Inactivated Influenza Vaccine: Intramuscular injection of vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With rtPCR-confirmed CDC-defined Influenza-Like Illness</title>
          <description>rtPCR-confirmed CDC-defined ILI that begins at least 14 days post-vaccination caused by any influenza strain.</description>
          <population>The efficacy population includes all randomized subjects who received study vaccine and provided any follow-up for ILI beginning at least 14 days following vaccine administration.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4303"/>
                <count group_id="O2" value="4301"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                    <measurement group_id="O2" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Seroconversion</title>
        <description>Seroconversion rates (SCR) for all four antigens in a preselected subset of subjects.</description>
        <time_frame>Days 0 through 28</time_frame>
        <population>The immunogenicity population includes all randomized subjects at the specific study sites pre-selected for serology who received study vaccine and provided serum samples on Days 0 and 28 for serologic testing.</population>
        <group_list>
          <group group_id="O1">
            <title>Flublok Quadrivalent Influenza Vaccine</title>
            <description>Intramuscular injection of vaccine containing 4 x 45µg (180µg total) of each recombinant hemagglutinin (rHA) derived from influenza A/H1N1 and A/H3N2 and two lineages of influenza B viruses identified for the season in which the trial is conducted in a total volume of 0.5 mL
Flublok Quadrivalent Influenza Vaccine: Intramuscular injection of vaccine</description>
          </group>
          <group group_id="O2">
            <title>Inactivated Influenza Vaccine</title>
            <description>Intramuscular injection of vaccine contains 4 x 15µg (60µg total) of HA derived from the same influenza A/H1N1 and A/H3N2 and influenza B strains in a total volume of 0.5mL.
Inactivated Influenza Vaccine: Intramuscular injection of vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Seroconversion</title>
          <description>Seroconversion rates (SCR) for all four antigens in a preselected subset of subjects.</description>
          <population>The immunogenicity population includes all randomized subjects at the specific study sites pre-selected for serology who received study vaccine and provided serum samples on Days 0 and 28 for serologic testing.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="314"/>
                <count group_id="O2" value="300"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/California</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.9" lower_limit="39.3" upper_limit="50.6"/>
                    <measurement group_id="O2" value="49.0" lower_limit="43.2" upper_limit="54.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Texas</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.5" lower_limit="48.8" upper_limit="60.1"/>
                    <measurement group_id="O2" value="43.3" lower_limit="37.6" upper_limit="49.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Massachusetts</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.9" lower_limit="33.4" upper_limit="44.5"/>
                    <measurement group_id="O2" value="38.3" lower_limit="32.8" upper_limit="44.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.0" lower_limit="16.6" upper_limit="25.9"/>
                    <measurement group_id="O2" value="34.3" lower_limit="29.0" upper_limit="40.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Local Injection Site Reactogenicity</title>
        <description>Solicited events of injection site reactogenicity reported during Day 0-7.</description>
        <time_frame>Days 0 through 7</time_frame>
        <population>Solicited local reactogenicity events include subjects who recorded any injection site reaction data.</population>
        <group_list>
          <group group_id="O1">
            <title>Flublok Quadrivalent Influenza Vaccine</title>
            <description>Intramuscular injection of vaccine containing 4 x 45µg (180µg total) of each recombinant hemagglutinin (rHA) derived from influenza A/H1N1 and A/H3N2 and two lineages of influenza B viruses identified for the season in which the trial is conducted in a total volume of 0.5 mL
Flublok Quadrivalent Influenza Vaccine: Intramuscular injection of vaccine</description>
          </group>
          <group group_id="O2">
            <title>Inactivated Influenza Vaccine</title>
            <description>Intramuscular injection of vaccine contains 4 x 15µg (60µg total) of HA derived from the same influenza A/H1N1 and A/H3N2 and influenza B strains in a total volume of 0.5mL.
Inactivated Influenza Vaccine: Intramuscular injection of vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Local Injection Site Reactogenicity</title>
          <description>Solicited events of injection site reactogenicity reported during Day 0-7.</description>
          <population>Solicited local reactogenicity events include subjects who recorded any injection site reaction data.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4307"/>
                <count group_id="O2" value="4319"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1621"/>
                    <measurement group_id="O2" value="1745"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Unsolicited Adverse Events</title>
        <description>Unsolicited adverse events reported in the 28 days following vaccine administration.</description>
        <time_frame>Days 0 through 28</time_frame>
        <population>The safety population includes all randomized and vaccinated subjects who provided any safety data (solicited or unsolicited) following administration of study vaccine.</population>
        <group_list>
          <group group_id="O1">
            <title>Flublok Quadrivalent Influenza Vaccine</title>
            <description>Intramuscular injection of vaccine containing 4 x 45µg (180µg total) of each recombinant hemagglutinin (rHA) derived from influenza A/H1N1 and A/H3N2 and two lineages of influenza B viruses identified for the season in which the trial is conducted in a total volume of 0.5 mL
Flublok Quadrivalent Influenza Vaccine: Intramuscular injection of vaccine</description>
          </group>
          <group group_id="O2">
            <title>Inactivated Influenza Vaccine</title>
            <description>Intramuscular injection of vaccine contains 4 x 15µg (60µg total) of HA derived from the same influenza A/H1N1 and A/H3N2 and influenza B strains in a total volume of 0.5mL.
Inactivated Influenza Vaccine: Intramuscular injection of vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Unsolicited Adverse Events</title>
          <description>Unsolicited adverse events reported in the 28 days following vaccine administration.</description>
          <population>The safety population includes all randomized and vaccinated subjects who provided any safety data (solicited or unsolicited) following administration of study vaccine.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4328"/>
                <count group_id="O2" value="4344"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1345"/>
                    <measurement group_id="O2" value="1355"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Serious Adverse Events (SAEs) and Medically-attended Adverse Events (MAEs)</title>
        <description>Serious adverse events (SAEs) and medically-attended adverse events (MAEs) occurring during the period of follow-up through the influenza season (at least 6 months post-vaccination).
A MAE is an event that prompts an unplanned visit to a medical professional for diagnosis and/or treatment.</description>
        <time_frame>Day 0 through and up to 32 weeks post vaccination</time_frame>
        <population>The safety population includes all randomized and vaccinated subjects who provided any safety data (solicited or unsolicited) following administration of study vaccine.</population>
        <group_list>
          <group group_id="O1">
            <title>Flublok Quadrivalent Influenza Vaccine</title>
            <description>Intramuscular injection of vaccine containing 4 x 45µg (180µg total) of each recombinant hemagglutinin (rHA) derived from influenza A/H1N1 and A/H3N2 and two lineages of influenza B viruses identified for the season in which the trial is conducted in a total volume of 0.5 mL
Flublok Quadrivalent Influenza Vaccine: Intramuscular injection of vaccine</description>
          </group>
          <group group_id="O2">
            <title>Inactivated Influenza Vaccine</title>
            <description>Intramuscular injection of vaccine contains 4 x 15µg (60µg total) of HA derived from the same influenza A/H1N1 and A/H3N2 and influenza B strains in a total volume of 0.5mL.
Inactivated Influenza Vaccine: Intramuscular injection of vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Serious Adverse Events (SAEs) and Medically-attended Adverse Events (MAEs)</title>
          <description>Serious adverse events (SAEs) and medically-attended adverse events (MAEs) occurring during the period of follow-up through the influenza season (at least 6 months post-vaccination).
A MAE is an event that prompts an unplanned visit to a medical professional for diagnosis and/or treatment.</description>
          <population>The safety population includes all randomized and vaccinated subjects who provided any safety data (solicited or unsolicited) following administration of study vaccine.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4328"/>
                <count group_id="O2" value="4344"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="145"/>
                    <measurement group_id="O2" value="132"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="774"/>
                    <measurement group_id="O2" value="785"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Measure of Post-vaccination HAI GMTs</title>
        <description>GMT titers for all four antigens in a preselected subset of subjects.</description>
        <time_frame>Days 0 through 28</time_frame>
        <population>The immunogenicity population includes all randomized subjects at the specific study sites pre-selected for serology who received study vaccine and provided serum samples on Days 0 and 28 for serologic testing.</population>
        <group_list>
          <group group_id="O1">
            <title>Flublok Quadrivalent Influenza Vaccine</title>
            <description>Intramuscular injection of vaccine containing 4 x 45µg (180µg total) of each recombinant hemagglutinin (rHA) derived from influenza A/H1N1 and A/H3N2 and two lineages of influenza B viruses identified for the season in which the trial is conducted in a total volume of 0.5 mL
Flublok Quadrivalent Influenza Vaccine: Intramuscular injection of vaccine</description>
          </group>
          <group group_id="O2">
            <title>Inactivated Influenza Vaccine</title>
            <description>Intramuscular injection of vaccine contains 4 x 15µg (60µg total) of HA derived from the same influenza A/H1N1 and A/H3N2 and influenza B strains in a total volume of 0.5mL.
Inactivated Influenza Vaccine: Intramuscular injection of vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Measure of Post-vaccination HAI GMTs</title>
          <description>GMT titers for all four antigens in a preselected subset of subjects.</description>
          <population>The immunogenicity population includes all randomized subjects at the specific study sites pre-selected for serology who received study vaccine and provided serum samples on Days 0 and 28 for serologic testing.</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="314"/>
                <count group_id="O2" value="300"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 0 - A/California</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45" lower_limit="38" upper_limit="52"/>
                    <measurement group_id="O2" value="49" lower_limit="42" upper_limit="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28 - A/California</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="194" lower_limit="167" upper_limit="226"/>
                    <measurement group_id="O2" value="224" lower_limit="197" upper_limit="255"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 0 - A/Texas</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88" lower_limit="74" upper_limit="104"/>
                    <measurement group_id="O2" value="100" lower_limit="84" upper_limit="119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28 - A/Texas</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="530" lower_limit="470" upper_limit="597"/>
                    <measurement group_id="O2" value="366" lower_limit="325" upper_limit="412"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 0 - B/Massachusetts</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17" lower_limit="15" upper_limit="20"/>
                    <measurement group_id="O2" value="18" lower_limit="16" upper_limit="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28 - B/Massachusetts</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56" lower_limit="49" upper_limit="64"/>
                    <measurement group_id="O2" value="58" lower_limit="51" upper_limit="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 0 - B/Brisbane</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14" lower_limit="12" upper_limit="15"/>
                    <measurement group_id="O2" value="15" lower_limit="13" upper_limit="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28 - B/Brisbane</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30" lower_limit="26" upper_limit="34"/>
                    <measurement group_id="O2" value="44" lower_limit="39" upper_limit="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Systemic Reactogenicity</title>
        <description>Solicited events of systemic reactogenicity reported during Day 0-7.</description>
        <time_frame>Days 0 through 7</time_frame>
        <population>Solicited systemic reactogenicity events include subjects who recorded any systemic reaction data.</population>
        <group_list>
          <group group_id="O1">
            <title>Flublok Quadrivalent Influenza Vaccine</title>
            <description>Intramuscular injection of vaccine containing 4 x 45µg (180µg total) of each recombinant hemagglutinin (rHA) derived from influenza A/H1N1 and A/H3N2 and two lineages of influenza B viruses identified for the season in which the trial is conducted in a total volume of 0.5 mL
Flublok Quadrivalent Influenza Vaccine: Intramuscular injection of vaccine</description>
          </group>
          <group group_id="O2">
            <title>Inactivated Influenza Vaccine</title>
            <description>Intramuscular injection of vaccine contains 4 x 15µg (60µg total) of HA derived from the same influenza A/H1N1 and A/H3N2 and influenza B strains in a total volume of 0.5mL.
Inactivated Influenza Vaccine: Intramuscular injection of vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Systemic Reactogenicity</title>
          <description>Solicited events of systemic reactogenicity reported during Day 0-7.</description>
          <population>Solicited systemic reactogenicity events include subjects who recorded any systemic reaction data.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4306"/>
                <count group_id="O2" value="4318"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1077"/>
                    <measurement group_id="O2" value="1106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From time vaccination until the end of the influenza season (~6 months).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Flublok Quadrivalent Influenza Vaccine</title>
          <description>Intramuscular injection of vaccine containing 4 x 45µg (180µg total) of each recombinant hemagglutinin (rHA) derived from influenza A/H1N1 and A/H3N2 and two lineages of influenza B viruses identified for the season in which the trial is conducted in a total volume of 0.5 mL
Flublok Quadrivalent Influenza Vaccine: Intramuscular injection of vaccine</description>
        </group>
        <group group_id="E2">
          <title>Inactivated Influenza Vaccine</title>
          <description>Intramuscular injection of vaccine contains 4 x 15µg (60µg total) of HA derived from the same influenza A/H1N1 and A/H3N2 and influenza B strains in a total volume of 0.5mL.
Inactivated Influenza Vaccine: Intramuscular injection of vaccine</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (17.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="145" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="132" subjects_at_risk="4344"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Microcytic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Thrombocytosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4344"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Cardiac tamponade</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Cardiogenic shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Cardiovascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Coronary artery insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Coronary artery thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Ischaemic cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Sick sinus syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4344"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4344"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Diverticulum intestinal haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Colitis ischaemic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Cyclic vomiting syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Diverticulum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Food poisoning</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Hiatus hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Intestinal perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Volvulus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4344"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Drug withdrawal syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Hernia obstructive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4344"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Hepatic cirrhosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Hepatic haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Hepatitis alcoholic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4344"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Lung Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Abscess intestinal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Endocarditis staphylococcal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Eye abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Gangrene</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Osteomyelitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Osteomyelitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Salmonellosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Urinary tract infection fungal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4344"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Craniocerebral injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Toxicity to various agents</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Cervical vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Stab wound</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Wound complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4344"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Haematocrit decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>International normalised ratio increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Troponin increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4344"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Failure to thrive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Lactic acidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Obesity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4344"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Intervertebral disc degeneration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Spinal column stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Intervertebral disc compression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Rhabdomyolysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Tenosynovitis stenosans</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4344"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Hepatic cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of lung</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Abdominal wall neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>B-cell lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Bladder neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Colorectal cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Colorectal cancer recurrent</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Invasive ductal breast carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Metastases to liver</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Oesophageal carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Renal cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Rhabdomyoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Testis cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Thyroid cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Thyroid neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Transitional cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4344"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Embolic stroke</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Haemorrhagic stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Lacunar infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Lumbar radiculopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Myelomalacia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Sinus headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Thalamic infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4344"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4344"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Bladder outlet obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Calculus ureteric</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Renal necrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4344"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Cystocele</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Menorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Uterine disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4344"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Aspiration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4344"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4344"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Knee arthroplasty</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Abdominal hernia repair</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Alcohol detoxification</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Drug detoxification</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Gastric bypass</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Hernia repair</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Hip arthroplasty</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Inguinal hernia repair</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Intestinal resection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Joint surgery</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Rotator cuff repair</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4344"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Aortic aneurysm rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Aortic dissection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Circulatory collapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4344"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA (17.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1122" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="1206" subjects_at_risk="4344"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="186" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="199" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="106" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="100" subjects_at_risk="4344"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="129" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="156" subjects_at_risk="4344"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="95" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="79" subjects_at_risk="4344"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="143" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="145" subjects_at_risk="4344"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="226" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="253" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="178" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="177" subjects_at_risk="4344"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" subjects_affected="59" subjects_at_risk="4328"/>
                <counts group_id="E2" subjects_affected="97" subjects_at_risk="4344"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Lisa M. Dunkle, M.D., Chief Medical Officer</name_or_title>
      <organization>Protein Sciences Corporation</organization>
      <phone>203-599-6064 ext 153</phone>
      <email>ldunkle@proteinsciences.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

